Steroid-refractory courses of graft-versus-host disease are life-threatening complications after allogeneic stem cell transplantation. Evidence is accumulating that steroid-refractory graftversus-host disease courses associate with endothelial distress.
Introduction
Steroid-refractory acute graft-versus-host disease (GVHD) is a life-threatening complication following allogeneic stem cell transplantation (allo-SCT). A significant proportion of patients succumb to this condition despite the administration of a plethora of immunosuppressive drugs 1 . This non-response to intensive immunosuppression along with our previous observations support a working hypothesis that alloreactive T cell responses induce acute GVHD. Consequently, immunosuppressive therapy is able to effectively erase this immune response and cure most patients. However, a minority of patients (refractory despite effective immune depletion) progress to a fatal inflammatory process based on a pre-existing, so far illdefined endothelial vulnerability [2] [3] [4] .
Angiopoietin-2 is a Tie2-ligand enhancing pro-inflammatory effects of tumor necrosis factor alpha (TNF-α) on endothelial cells 5 . We have previously shown that in patients developing grade 3-4 GVHD, high pre-transplant Angiopoietin-2 serum levels are correlated with steroid refractoriness and fatal outcome but not with GVHD risk itself, suggesting a role for endothelial vulnerability in the pathogenesis of refractory GVHD 2, 3 .
In 1980 nitric oxide (NO) was identified as endothelial derived relaxing factor , a potent vasodilator that is intrinsically tied to endothelial cell homeostasis 6, 7 . NO is labile with a very short half-life (< 4 seconds in biological solutions) and is rapidly oxidised to nitrite and then nitrate by oxygenated hemoglobin before being excreted into the urine 7 . Serum nitrates are therefore considered as indicators of NO production in vivo 8, 9 . Diet contributes about half of the serum nitrate levels, whereas 90% of circulating nitrites in fasting humans are derived from the constitutive endothelial and brain isoforms of NO synthase (eNOS, nNOS) 10 .
Excessive levels of NO are produced by the inducible isoform of NOS (iNOS) in numerous cell types including immune effector cells 11 . Furthermore, elevated iNOS-derived NO levels were demonstrated in various autoimmune diseases 12 as well as in solid organ allograft 4 rejection 13 . In the setting of alloSCT NO was shown to facilitate alloengraftment and iNOS inhibitors were reported to reduce mortality of experimental GVHD 14 .
Statins lower cholesterin levels by inhibiting 3-hydroxy-3-methyl-CoA (HMG-CoA) reductase and are therefore used to prevent complications of arteriosclerotic diseases. Besides protective effects on endothelial cells 15, 16 , statins also modulate the immune system 17, 18 .
This has led several investigators to test statins in the context of alloSCT yielding inconsistent results. Reduction of acute GVHD or mortality after alloSCT in mice and humans was shown in some studies [19] [20] [21] but not in others 22, 23 . However, studies focussing on the effect of statins on the prevention or treatment of refractory GVHD and associated endothelial alterations are lacking.
The purpose of the present retrospective study was to investigate if the predictive value of pre-transplant levels of parameters representing endothelial cell function such as Angiopoietin-2 could be further refined by measuring pre-transplant nitrate levels, and to analyze if negative influences on clinical outcome could be attenuated by (potentially endothelium-protective) concomitant statin administration.
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Methods
Patient eligibility
Patients were eligible for this study if they had undergone alloSCT at our institution between 06/2002 and 12/2011 and had available blood samples for nitrate measurement (collected directly before start of conditioning chemotherapy prior to alloSCT). Written informed consent to sample and data collection according to the declaration of Helsinki was obtained in all eligible patients as well as normal donors (n=49) and sample and data collection was approved by the responsible Institutional Review Board.
GVHD prophylaxis, treatment, and supportive care
GVHD prophylaxis was performed as previously described 2, 3 and remained unchanged over the whole study period. GVHD was clinically and histologically diagnosed and graded using standard criteria 24 . Steroid-refractory GVHD was defined as histologically confirmed disease not responding to standard prednisone therapy (2x1 mg/kg body weight, for intestinal GVHD combined with mycofenolate mofetil 2x1 g/d) and requiring second-line salvage immunosuppressive therapy which was generally pentostatin 25 (see suppl. Methods).
ELISAs, Multiplex analyses, Nitrate assay and Western blots
Serum levels of Angiopoietin-2 were quantified by the multiplex protein array technology in 327 patients as reported before 3 . TNF levels were measured in 417 patients by ELISA (BD Biosciences Pharmingen, San Diego, CA, USA). Determination of serum nitrates (n=417) was performed using the Griess Reagent System (see supplemental methods).
For western blots the following monoclonal antibodies were used: rabbit anti-TNF-α (Cell Signaling Technology through New England Biolabs, Frankfurt, Germany), mouse anti-iNOS (2D2-B2) (R&D Systems, Wiesbaden-Nordenstadt, Germany) and mouse anti-β-actin (AC- 6 15) (Abcam, Cambridge, UK). Corresponding secondary antibodies were purchased from Sigma-Aldrich (Deisenhofen, Germany).
Statistical analysis
Categorical and continuous variables of patient characteristics were compared using Fisher's exact test and the Mann-Whitney test, respectively. Cumulative incidences of refractory GVHD were compared using the logrank test.
For the choice of cut-offs for nitrates and Angiopoietin-2 see suppl. Methods.
Non-relapse mortality (NRM) was calculated as the time from alloSCT to death in the absence of relapse considering recurrence of the underlying malignancy as competing event.
NRM of different groups of patients was compared with the Grays test [26] [27] [28] .
Cox proportional hazard regression models were performed for multivariate analysis of predictors of grade 3-4 and refractory GVHD, and multivariate competing risk proportional subdistribution hazards regression models were set up to adjust for the impact of potential confounders of the effect of nitrate levels on sensitive GVHD and NRM: donor, conditioning, age, and disease specific remission score 26, 28 .
Calculations were done using the statistical software environment R, version 2. 
Results
Patient characteristics
Of 828 patients who underwent alloSCT in our institution between June 2002 and December 2011, 417 met the eligibility criteria for this study (serum nitrate levels measurable).
Angiopoietin-2 was measured in 327 patients as reported previously 3 . Collectively, 182 of 417 patients (44%) developed at least one episode of acute GVHD. Patients were categorized based on concomitant statin therapy starting at least 1 day before transplantation. Group 1 (n =258): patients without pravastatin; group 2 (n=159): patients with pravastatin. As shown in Table 1 , baseline and transplant associated characteristics did not differ between the two groups of patients except for age distribution, donor use, disease status and liver GVHD.
Patients with statins were significantly older and were significantly more often transplanted from matched unrelated donor (MUD). They were also more often in disease remission status 1 and had more often liver GVHD. No statin-associated toxicities requiring statin withdrawal were observed.
In addition, patients were grouped based on pre-transplant nitrate levels (low: ≤ 26.5 µM, n=169; high: >26.5 µM, n=248) (suppl. Table 1 , suppl. methods). Again, no significant differences between the two cohorts could be identified except that patients with high nitrates were significantly younger, were more often female, were more often in disease remission status 1 and had less often AML.
High pre-transplant serum nitrate levels predict steroid-refractory GVHD and NRM
In the absence of statins, pre-transplant serum nitrates exceeding 26.5 µM predict steroidrefractory GVHD (p=0.026) and NRM (p=0.028) ( Figure 1A ). Multivariate analyses confirmed serum nitrates as independent predictors of steroid-refractory GVHD and NRM ( 
Lack of correlation between serum nitrates and systemic iNOS activity
Increased NO levels could be generated by iNOS 29 . Because iNOS is induced during inflammation, we tried to link inflammatory markers with pre-transplant nitrates. Differences in serum nitrate levels did not correlate with pre-transplant serum levels of TNF (Pearson correlation: r 2 =0.1), C-reactive protein (CRP) (n=150, r 2 =0) or expression of iNOS in blood cells (suppl. Figure 1 ).
Reduced incidence of refractory GVHD in patients with high pre-transplant nitrates treated with statins
In contrast to patients with low pre-transplant nitrate levels (p=0.28, HR 1.66, 95% CI 0.66-4.17), patients with high pre-transplant nitrate levels had significantly reduced rates of refractory GVHD when pravastatin was used from day -1 (p=0.031, HR 0.19 95% CI 0.05-0.86) (Figure 1B) .
High pre-transplant Angiopoietin-2 and nitrate levels independently predict outcome of GVHD
In multivariate analyses, pretransplant nitrate and Angiopoietin-2 levels were independent predictors of steroid refractory GVHD ( Table 2) . Consequently, patients with both risk factors had the highest risk to develop a steroid-refractory GVHD and NRM (p=0.0007 and p=0.021, respectively) ( Figure 2 ). Among patients with both risk factors (Angiopoietin-2 >1,000 pg/mL and nitrate >26.5 µM), statin intake showed a non-significant trend for lower steroid refractory GVHD incidence (p=0.26, HR 0.48, 95% CI 0.10-1.87), with lack of significance most likely due to the low number of patients on statins (n=20) in this high risk 9 group. Again subgroup analysis revealed that NRM of the high risk group was only elevated in patients with GVHD (p=0.0006, HR 3.73, 95% CI 1.75-8.83) but not in patients without GVHD (Figure 3 ).
Multivariate analysis of the whole study population not restricting the analysis to any subgroup confirmed that low nitrate levels were associated with reduced refractory GVHD incidence but not overall grade 3-4 GVHD incidence ( Table 2) . Furthermore, high nitrate levels (>26.5 µM) were associated with increased NRM incidence whereas statin intake was associated with significantly reduced NRM incidence ( Table 2) .
Discussion
In our retrospective study we identify a cohort of patients that is at high risk of developing steroid-refractory disease if an allogeneic T-cell response strikes to induce GVHD. We have previously provided evidence that steroid-refractory but not steroid-sensitive GVHD is associated with endothelial distress 2, 3 . In particular cytokines indicating endothelial damage such as Angiopoietin-2, soluble thrombomodulin, hepatocyte growth factor, and interleukin 8
were exclusively elevated in patients with refractory GVHD when measured in serum on day 50 and 100 after alloSCT 3 . Here we report that these patients can be identified prior to alloSCT by high serum nitrate and Angiopoietin-2 concentrations. The risk of steroidrefractory GVHD in this high risk group appears to be reduced by statin administration during the transplant and early post-transplant period.
The concept of endothelial vulnerability suggests that the development of refractory disease is at least in part a characteristic of the recipient's endothelial cell system and hence can be predicted before transplantation 3 . Angiopoietin-2 clearly mediates endothelial stress 5 and we could previously show that in patients who develop severe (grade 3-4) GVHD high pretransplant Angiopoietin-2 were associated with steroid refractoriness 2, 3 .
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Nitrates are the final oxidative degradation product of NO, a critical regulator of vascular homeostasis, neurotransmission and host defence 30, 31 . We show that patients with elevated pre-transplant nitrate levels are more likely to develop a steroid refractory GVHD translating into a higher NRM incidence.
Increased NO levels could be caused by inducible iNOS 29 . To exclude that iNOS activity contributes to the serum nitrate levels measured in our study, we have tried to link inflammatory markers with nitrates measured prior to alloSCT. However, neither serum levels of TNF, CRP nor intracellular iNOS in peripheral blood mononuclear cells correlated with nitrate levels. It is therefore unlikely that increased pre-transplant iNOS activity due to inflammatory conditions has caused the increased rates of refractory GVHD in the high nitrate cohort. Alternatively eNOS activity reflecting endothelial stress may have significantly contributed to increased nitrate levels measured in our study cohort. In line with our findings animal atherosclerosis models demonstrated augmented expression of eNOS, at least in early stages 32 . In addition, single nucleotide polymorphisms of the eNOS genes have also been shown to alter baseline nitrate levels prior to alloSCT 33 . Most importantly, nitrate itself has also been recognized as a storage pool for NO-like bioactivity, and can physiologically be recycled to form NO 34, 35 . The bioactivation of nitrate from dietary or endogenous sources requires its initial reduction to nitrite 35 . As mammals lack specific and effective nitrate reductase enzymes, this conversion is therefore mainly carried out by commensal bacteria on body surfaces and in the gastrointestinal tract (including mouth/saliva) 36 . This evokes a fascinating, nitrate/NO-associated relationship of commensal bacteria, mucosal surface immunity and endothelial cell function that deserves further attention in the context of GVHD pathophysiology.
A major finding of this study is the observation that statins seem to eliminate the increased risk of GVHD refractoriness associated with elevated pre-transplant nitrate serum levels.
Statins were reported to attenuate innate and adaptive immune responses 20 and similarly 11 protect endothelial cells 15 . As refractory GVHD patients are insensitive to the immunosuppressive activity of a wide variety of drugs, it is hard to conceive how the reduced incidence of refractory GVHD might be explained by statins suppressing immune responses.
We rather hypothesize that the endothelial protective activity of statins is at least in part responsible for reduction of refractory GVHD incidence under statin treatment. Statins were shown to exert pleiotropic, concentration-dependent effects including eNOS induction and vessel stabilization 16, 37, 38 . Recently, we have reported that intestinal biopsies of refractory GVHD patients associate with an abnormal loss of endothelial Thrombomodulin expression 4 .
It is possible that statins might affect local endothelial Thrombomodulin expression, a hypothesis which is currently being investigated. Clearly, it has to be taken into account that patients with and without statins were consecutive and not concurrent in this study. Therefore it can not be ruled out that other yet unrecognized time-dependent factors may have accounted for the effects observed. However, the lack of statin effects on patients with low nitrate levels argues for the specificity of our observation.
Finally, we have also demonstrated that pre-transplant nitrate levels are predictive for steroid refractory GVHD and NRM independently of Angiopoietin-2. The presence of both risk factors prior to alloSCT identifies a group of patients who have the highest risk of developing refractory GVHD. This information could potentially be used to guide immunosuppression post transplantation. Furthermore, a more selective use of statins for endothelial high risk patients who are likely to profit should be explored in future studies. Statin intake showed a reduced trend for refractory GVHD, most likely due to the small numbers of patients on statins in this high risk group. Subgroup analysis revealed that NRM of the high risk group was elevated in patients with GVHD but not in patients without GVHD. This observation strongly supports our hypothesis that endothelial vulnerability causes transplant related mortality only in patients who experience a severe immune attack. 12 In summary, within the limits of a retrospective analysis our study shows that patients at high risk of steroid-refractory GVHD can be identified already prior to allo-SCT by nitrates and Angiopoietin-2, both relevant markers of endothelial cell physiology, thereby further supporting the "endothelial vulnerability" hypothesis. Given the dismal prognosis of refractory GVHD patients, together with the observed lack of statin-associated toxicity, we believe that further studies on the role of the endothelium and statin administration on GVHD outcome are highly warranted.
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Nitrate assays
Determination of nitrate in serum was performed using the Griess Reagent System. Ten microliters of serum and 70 µl MilliQ water were mixed and incubated in a microtiter plate We therefore chose a cut-off of 26.5 µM to categorize patients into high and low pretransplant nitrate cohorts.
Statistical Analyses
The cut-off for nitrates was chosen based on the maximally selected rank statistics with regard to refractory GVHD incidence among patients without statins. The R package maxstat 0.7-17 was used and yielded three maxima between 19 and 35 µM at 22, 26 and 30 µM. Because the median of the normal subject cohort was at 26.5 µM and this most likely reflects a situation not influenced by chemotherapy treatment, we choose 26.5 µM as a cut-off. The cut-off for ANG2 at 1,000 pg/mL was also based on maximally selected rank statistics and was previously published by our group 6 .
